L2Capital Deep research, on demand
Login Register
MRNA logo

MRNA · Moderna, Inc.

Last updated Nov 06, 2026
Recommendation
SELL
12-Month Target
$185.00
-28.7% return
Reference Price
$259.53
November 06, 2026
Download PDF Read HTML
INSTITUTIONAL MEMORANDUM · MRNA NASDAQ 100

Has Oncology Euphoria Gone Too Far?

Breakthrough efficacy is real, but the valuation already assumes broad tumor success.

L2 Capital Institutional Verdict

Moderna, Inc. (MRNA) is currently rated SELL with a 12-month valuation target of $185.00 (implied return: -28.7%). Based on forensic analysis of SEC filings and audited cash flows, High conviction reflects Management raised 2026 revenue growth guidance to 15%-25% from up to 10%, implying approximately $2.24-$2.43 billion of full-year revenue..

Executive Thesis

SELL: Moderna's $103 billion equity value discounts an oncology franchise far beyond currently de-risked melanoma, despite a raised 2026 revenue outlook. Intismeran's Phase 3 efficacy, proprietary neoantigen engine, and Merck partnership establish a credible platform moat. Yet quarterly profitability is seasonal, nine-month free cash flow remains deeply negative, respiratory revenue is still COVID-heavy, and oncology economics are shared equally. Trim or exit into strength; re-enter below our $185 risk-adjusted value or after additional tumor validation.

Key Actionable Findings

Click any finding to interrogate with Andy ↗
Management raised 2026 revenue growth guidance to 15%-25% from up to 10%, implying approximately $2.24-$2.43 billion of full-year revenue.
Intismeran reduced melanoma recurrence or death risk by 42%, but Moderna shares worldwide development costs and profits equally with Merck.
Q3 profitability masks a $1.96 billion nine-month net loss and approximately $2.86 billion of negative year-to-date free cash flow.
The $8.0 billion liquidity balance includes convertible financing; gross debt is approximately $3.55 billion and the stock trades above the notes' initial conversion price.

Frequently Asked Questions: MRNA

What is L2 Capital's investment rating and price target for MRNA?

L2 Capital currently maintains an institutional rating of SELL on Moderna, Inc. (MRNA) with a 12-month target price of $185.00 (implied return: -28.7%), backed by High conviction.

What is the core investment thesis for MRNA?

SELL: Moderna's $103 billion equity value discounts an oncology franchise far beyond currently de-risked melanoma, despite a raised 2026 revenue outlook. Intismeran's Phase 3 efficacy, proprietary neoantigen engine, and Merck partnership establish a credible platform moat. Yet quarterly profitability is seasonal, nine-month free cash flow remains deeply negative, respiratory revenue is still COVID-heavy, and oncology economics are shared equally. Trim or exit into strength; re-enter below our $185 risk-adjusted value or after additional tumor validation.

What are MRNA's latest audited financial fundamentals?

According to audited SEC EDGAR filings, Moderna, Inc. reported total revenue of $1.94B (-39.9% YoY), Gross Margin of N/A, Free Cash Flow of -$2.06B, and Net Debt of -$2.00B.

What key risks and catalyst factors should investors monitor for MRNA?
  • Management raised 2026 revenue growth guidance to 15%-25% from up to 10%, implying approximately $2.24-$2.43 billion of full-year revenue.
  • Intismeran reduced melanoma recurrence or death risk by 42%, but Moderna shares worldwide development costs and profits equally with Merck.
  • Q3 profitability masks a $1.96 billion nine-month net loss and approximately $2.86 billion of negative year-to-date free cash flow.
  • The $8.0 billion liquidity balance includes convertible financing; gross debt is approximately $3.55 billion and the stock trades above the notes' initial conversion price.